DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Overview of attention for article published in Molecular Cancer, October 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#18 of 1,710)
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 9 news outlets

twitter: 4 X users

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 19 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 4,382 followers.

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes | Molecular Cancer | Full Text https://t.co/xaxQzKFsaz

07 Dec 2021

Reply Repost Favourite

A joint collaborative effort led by Prof Navin from @NTU_LKCMedicine, uncovering the role of the loss of DDX3X and its association with chemoresistance in DLBCL. Check it out here! https://t.co/RlCnUzeKt4

17 Oct 2021

Reply Repost Favourite

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes #lymphoma #lymsm https://t.co/zG1nco7U2E

17 Oct 2021

Reply Repost Favourite

DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes #lymphoma #lymsm https://t.co/hfCXc4WfwA

16 Oct 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 1 additional X posts.